CAS 877387-37-6

Fórmula: C27H31NO3

InChI: InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26-

Clave InChI: ZVSFNBNLNLXEFQ-RQZHXJHFSA-N

SMILES: CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCO)\C2=CC=CC=C2)/C3=CC=C(C=C3)O

GSK5182

CAS: 877387-37-6

GSK5182

Fórmula: C₂₇H₃₁NO₃

Pureza: ≥95%

Peso molecular: 417.54

Ref: 54-BUP04654

GSK5182

CAS: 877387-37-6

Fórmula: C₂₇H₃₁NO₃

Pureza: 98%

Peso molecular: 417.5399

Ref: IN-DA01V3O1

GSK5182

CAS: 877387-37-6

(Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-2-phenylpent-1-en-1-yl)phenol

Fórmula: C₂₇H₃₁NO₃

Pureza: 98%

Peso molecular: 417.54

Ref: IN-DG00800860

GSK5182

CAS: 877387-37-6

GSK5182 is a highly selective inverse estrogen-related receptor γ agonist (IC50 : 79 nM)

Fórmula: C₂₇H₃₁NO₃

Pureza: 97.63% - 99.64%

Forma y color: Solid

Peso molecular: 417.5399

Ref: TM-T8370

GSK5182

Producto controlado

CAS: 877387-37-6

GSK5182 is a drug that was originally developed as an anti-obesity drug and has since been used to treat metabolic disorders. It is a small molecule that inhibits the protein phosphatase 2A, which is involved in regulating transcriptional activity. GSK5182 has been shown to reduce ovarian activity in rats and decrease energy metabolism. This drug also inhibits mitochondrial membrane potential and the transcription of pro-apoptotic proteins. GSK5182 has also been shown to have therapeutic effects on cardiac disease, hepatic steatosis, and natural compounds.

Fórmula: C₂₇H₃₁NO₃

Pureza: Min. 95%

Peso molecular: 417.5 g/mol

Ref: 3D-CKB38737